• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

In an­oth­er win for ri­val Aim­mune, FDA press­es pause on DB­V's peanut patch with ad­di­tion­al ques­tions

6 years ago
R&D

‘It’s like the tor­toise and the hare’: A pan­dem­ic puts Sanofi’s $600M bet to the test

6 years ago
R&D
Coronavirus

Five days af­ter re­gain­ing the helm at Cure­Vac — and 1 day af­ter con­tro­ver­sy erupt­ed — In­g­mar Ho­err makes sur­prise ...

6 years ago
People

An­oth­er an­tibi­ot­ic mak­er bites the dust, as Tetraphase is swal­lowed for cheap

6 years ago
Deals
Pharma

Bio­gen staffer fled to Chi­na in search of emer­gency Covid-19 test­ing, care — and now faces crim­i­nal charges

6 years ago
People
Coronavirus

EMA of­fers free sci­en­tif­ic ad­vice for Covid-19 de­vel­op­ers

6 years ago
Coronavirus

Unum gets a re­prieve from the FDA — par­tial hold lift­ed af­ter 9 days

6 years ago
R&D

'We're led by the sci­ence': UK's plan to de­lay coro­n­avirus peak and pur­sue herd im­mu­ni­ty trig­gers up­roar

6 years ago
Coronavirus

BioN­Tech teams up with Fo­s­un Phar­ma to test Covid-19 mR­NA vac­cine in Chi­na — and scores $50M in­vest­ment

6 years ago
R&D
Coronavirus

Covid-19 roundup: Re­gen­eron, Sanofi launch coro­n­avirus pro­gram; NIH staffer tests pos­i­tive for coro­n­avirus, Mod­er­na ...

6 years ago
R&D
Coronavirus

Trump ad­min­is­tra­tion tries to lure Ger­man coro­n­avirus vac­cine mak­er to US — re­ports

6 years ago
R&D
Coronavirus

Bio­gen’s Covid-19 tal­ly breaks past the 100 mark, feed­ing the state to­tal as the con­ta­gion wreaks hav­oc

6 years ago
Coronavirus

Biotech en­tre­pre­neurs Arie Bellde­grun and Cedric Fran­cois test pos­i­tive for Covid-19 — and here's why they want you ...

6 years ago
People
Coronavirus

Cure­Vac’s In­g­mar Ho­err tells us why he re­turned to take on a pan­dem­ic; NGM los­es a pres­i­dent

6 years ago
Peer Review

Baven­cio from Mer­ck KGaA, Pfiz­er en­coun­ters yet an­oth­er tri­al set­back

6 years ago
R&D

The E100 biotech sur­vey: Ex­ecs are hun­ker­ing down for the pan­dem­ic, wor­ried about longterm fall­out — but ea­ger to ...

6 years ago
Special

Eli Lil­ly teams with an­ti­body up­start Ab­Cellera in coro­n­avirus hunt

6 years ago
R&D
Coronavirus

FDA of­fers Roche an emer­gency OK for coro­n­avirus test­ing tech — eas­ing a crit­i­cal log­jam

6 years ago
FDA+
Coronavirus

Taint­ed do­na­tions from stool bank reignite safe­ty con­cerns about poop trans­plants

6 years ago
R&D
FDA+

Part­nered with Gilead and Sanofi, pro­tein degra­da­tion spe­cial­ist Nurix bags $120M to chart its own clin­i­cal path

6 years ago
Financing

Bio­gen out­break con­tin­ues to spur new coro­n­avirus cas­es in Mass­a­chu­setts as health of­fi­cials strug­gle to keep up with ...

6 years ago
R&D
Coronavirus

A one-time biotech uni­corn gets slaugh­tered as lead pro­gram is scrapped, high­light­ing lin­ger­ing trou­ble

6 years ago
R&D
FDA+

Cure­Vac founder back at the helm; Mer­ck ex­tends im­munomod­u­la­to­ry drug dis­cov­ery pro­gram with Sutro

6 years ago
News Briefing

Coro­n­avirus: WHO de­clares pan­dem­ic, EMA meet­ings go vir­tu­al

6 years ago
FDA+
First page Previous page 844845846847848849850 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.